Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icotinib vs Chemotherapy in EGFR-mutated Lung Adenocarcinoma
NCT01719536Phase 3Completed
- Sponsor
- Betta Pharmaceuticals
- Start
- Dec 2012
- Primary completion
- Sep 2016
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of icotinib in lung adenocarcinoma (2 arms), sponsored by Betta Pharmaceuticals. Primary endpoint: Progression-Free Survival at 12 months. Started Dec 2012; status: completed.
02
Drugs
icotinib
03
Conditions
lung adenocarcinoma
Beyond the preview
Go deeper on NCT01719536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01719536.